Business Description
Phathom Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US71722W1071
Share Class Description:
PHAT: Ordinary sharesDescription
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.74 | |||||
| Equity-to-Asset | -0.18 | |||||
| Debt-to-Equity | -1.91 | |||||
| Debt-to-EBITDA | -0.87 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.4 | |||||
| 3-Year FCF Growth Rate | -8.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.47 | |||||
| 9-Day RSI | 35.28 | |||||
| 14-Day RSI | 41.68 | |||||
| 6-1 Month Momentum % | 16.11 | |||||
| 12-1 Month Momentum % | 2.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.25 | |||||
| Quick Ratio | 10.22 | |||||
| Cash Ratio | 9.83 | |||||
| Days Sales Outstanding | 876.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.7 | |||||
| Shareholder Yield % | -31.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -24532.55 | |||||
| Net Margin % | -29558.94 | |||||
| FCF Margin % | -20412.61 | |||||
| ROA % | -82.3 | |||||
| ROIC % | -881.42 | |||||
| ROC (Joel Greenblatt) % | -4645.63 | |||||
| ROCE % | -72.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 774.19 | |||||
| EV-to-EBIT | -1.83 | |||||
| EV-to-EBITDA | -1.84 | |||||
| EV-to-Revenue | 428.1 | |||||
| EV-to-Forward-Revenue | 6.6 | |||||
| EV-to-FCF | -2.09 | |||||
| Earnings Yield (Greenblatt) % | -54.64 | |||||
| FCF Yield % | -25.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PHAT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Phathom Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.682 | ||
| EPS (TTM) ($) | -3.94 | ||
| Beta | 0.19 | ||
| Volatility % | 100.6 | ||
| 14-Day RSI | 41.68 | ||
| 14-Day ATR ($) | 0.710364 | ||
| 20-Day SMA ($) | 10.1435 | ||
| 12-1 Month Momentum % | 2.45 | ||
| 52-Week Range ($) | 6.065 - 17.0185 | ||
| Shares Outstanding (Mil) | 58.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Phathom Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Phathom Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Phathom Pharmaceuticals Inc Frequently Asked Questions
What is Phathom Pharmaceuticals Inc(PHAT)'s stock price today?
The current price of PHAT is $9.28. The 52 week high of PHAT is $17.02 and 52 week low is $6.07.
When is next earnings date of Phathom Pharmaceuticals Inc(PHAT)?
The next earnings date of Phathom Pharmaceuticals Inc(PHAT) is 2024-05-10 Est..
Does Phathom Pharmaceuticals Inc(PHAT) pay dividends? If so, how much?
Phathom Pharmaceuticals Inc(PHAT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers